Publication | Open Access

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine TrialVaccine EfficacyNon-inferiority TrialBooster DoseCovid-19 VaccineMedicineCovid-19